NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
17.89
+0.30 (1.71%)
At close: May 16, 2025, 4:00 PM
17.44
-0.45 (-2.51%)
After-hours: May 16, 2025, 7:54 PM EDT
NovoCure Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for NovoCure stock ranges from a low of $27 to a high of $40. The average analyst price target of $32.83 forecasts a 83.51% increase in the stock price over the next year.
Price Target: $32.83 (+83.51%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $42 → $34 | Buy | Maintains | $42 → $34 | +90.05% | Apr 23, 2025 |
| Wedbush | Wedbush | Hold Maintains $29 → $27 | Hold | Maintains | $29 → $27 | +50.92% | Apr 16, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $29 → $28 | Hold | Maintains | $29 → $28 | +56.51% | Apr 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $38 | Strong Buy | Reiterates | $38 | +112.41% | Jan 14, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $28 → $42 | Buy | Maintains | $28 → $42 | +134.77% | Dec 13, 2024 |
Financial Forecast
Revenue This Year
638.85M
from 605.22M
Increased by 5.56%
Revenue Next Year
697.29M
from 638.85M
Increased by 9.15%
EPS This Year
-2.02
from -1.56
EPS Next Year
-2.05
from -2.02
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 666.7M | 746.9M | 885.6M | ||
| Avg | 638.9M | 697.3M | 794.5M | ||
| Low | 602.7M | 655.3M | 713.1M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.2% | 16.9% | 27.0% | ||
| Avg | 5.6% | 9.1% | 13.9% | ||
| Low | -0.4% | 2.6% | 2.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.62 | -1.53 | -0.92 | ||
| Avg | -2.02 | -2.05 | -1.50 | ||
| Low | -2.81 | -2.69 | -2.27 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.